
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Nuformix Plc | NFX | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.1025 | 0.1025 | 0.1025 | 0.1025 |
Industry Sector |
---|
NONEQUITY INVESTMENT INSTRUMENTS |
Top Posts |
---|
Posted at 02/6/2025 19:06 by washingmachine We have moved a lot lot further down the road medically verifying NXP200 since she was here, Odviously the share price does not reflect this yet !! Her letter sent to shareholders at the time, maybe still on the NFX website I've not checked, if not i may have a copy. |
Posted at 02/6/2025 17:26 by for fx sake "Dr Anne brindley who used to work for NFX Has strong connections with Astra Zeneca. She left : But issued a very confident letter on NFX002 On its market potential etc."Yeah, I remember her. What was the price she started and what was the price when she left? |
Posted at 02/6/2025 16:49 by washingmachine Dr Anne brindley who used to work for NFX Has strong connections with Astra Zeneca. She left : But issued a very confident letter on NFX002 On its market potential etc. |
Posted at 28/5/2025 22:48 by the gerbilator NFX has been making it light up like a xmas tree for weeks - beautiful |
Posted at 19/4/2025 10:17 by dicko80 Hopefully ODD status gets confirmed this week, with the committee meeting between 14th to 16th April.This confirmation should be the last piece of a jigsaw for a deal to be concluded for global sales deal IPO NFX came to the market with a reverse takeover of Leverett plc at a price of £12m IPO £12m - current mkt cap just £2m Any progress ? patents in place for to protect the rights for NPX002 in USA, Japan, Europe for worldwide sales deal Global sales potential USA Japan Europe The patents offer the opportunity for worldwide sales and as such the company could tie up a global deal package with potential annual sales of over $1bn made up of eligible patients of USA 10,000 @ £50k+ Japan 4,000 @ £40k+ Europe 11,000 @ £25k+ Commercial discussions have been ongoing for some time, due to the amount of monies at stake and the number of different options to be discussed with each interested party- upfront payments and milestones, royalty payments but at a company valuation of just £2m with discussions at an advanced stage now looks an opportunity to buy or add, with ODD potentially final piece of the jigsaw to be announced shortly, potential as soon as next week 2021 valuation Page 29 Bottom paragraph “global sales deal $360 - 450m” This just for NPX002 but 2021 numbers Recent IPF deal $780m Then we have 004 that outperforms AZ lunparza , expected annual sales of $10bn by 2028 NPX004 - blockbuster potential The Group discovered novel forms of olaparib, a drug currently marketed by AstraZeneca, as Lynparza®. Lynparza® was first approved in December 2014 for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation. Since then, it has secured similar approvals in breast, pancreatic and prostate cancers with further trials on-going. These approvals have propelled Lynparza® sales to US$2.6bn in 2022 with industry analysts forecasting annual sales of US$9.7bn by 2028. Subsequently, further preformulation and in-vitro studies allowed Nuformix to identify lead cocrystals to be progressed for further development. Results from in vitro dissolution studies demonstrated that the two lead NXP004 cocrystals OUT PERFORMED Lynparza®, both in terms of rate and extent of dissolution and release of olaparib. Preclinical deal £62m upfront £328m total value Slide 16 NFX £2m mkt cap |
Posted at 16/4/2025 19:16 by ball deap While visiting NYC for the first time, this is how we discovered NFX. It's easy to miss. They just have a advertising board on the sidewalk between eateries. Lots of crowds around. So on date night we decided to get some relaxing time in after long days of walking around. I must say that I love massages yet I don't get enough of them. They are very professional. I had ppl walking on my back while my massage therapist gave me the BEST massage I've ever had and filled me in about NFX. He did my whole body head to toe and in between toes and fingers. He didn't miss a spot while he wasn't too rough but he was able to get my knots out and put me to sleep for the first time. I WISH they were in my hometown of Rochdale. The price was reasonable. I wish I had booked more than just an hour. Perfect end to a long, busy day of touring NYC. |
Posted at 14/4/2025 10:39 by the gerbilator Anyway see how this gets handled.The Gerbilator - 14 Apr 2025 - 09:03:57 - 1008 of 1018 NUFORMIX September 2 Presentations - Massive Upside NFX - NFX LG there +26% to 38% on last close see what they get up to there |
Posted at 13/4/2025 18:07 by ball deap I had the opportunity for a NFX trade. I had an amazing trade with Sergio. Being in a trade, on my own, was a bit intimidating, but being with someone in on NFX made the experience so much easier. From the trade selections to the recommendations, every choice was made with a great deal of care and expertise. I'm already signed up for another NFX trip later this year! |
Posted at 03/4/2025 23:09 by ball deap Excellent investment Bruce @ NFX was knowledgeable, and effective in his guidance. Plenty funny as well too. The way our trade was executed allowed for most of the time to be spent in Barnsley with Mo, which was great! Not a ton of time for NFX two shirt spots, and definitely could have used more time at Rochdale. Would highly recommend NFX, (impeccable investment!) for any they facilitate! |
Posted at 28/3/2025 16:28 by ball deap If you're looking to set up somewhere for a bit and surf on NFX, NFX is a good bet. It's pretty chill but it can be pretty crowded with traders from all over Europe at times. You may end up competing for a NFX peak with 20 Polish people on foamies. But in that sense, those spots are pretty friendly. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions